Johnson & Johnson Enterprise Innovation Inc.

This early-phase study tests a new drug (JNJ-86974680) alone or with another drug and radiation for people with advanced non-small cell lung cancer. The main goal is to find a safe dose and check for side effects. About 126 adults with stage IIIB or IV lung cancer will take part.

This study tests whether adding an experimental drug (JNJ-90301900) to standard chemoradiation, followed by maintenance immunotherapy (durvalumab), can shrink tumors more effectively in people with locally advanced, inoperable stage III non-small cell lung cancer. About 130 parti…

This early-stage study tests whether a new drug called JNJ-90301900, injected directly into tumors, is safe and works well when combined with standard chemotherapy and radiation. About 30 adults with advanced head and neck cancer that has not spread will take part. The main goal …

This early-stage study tests a virus (JNJ-87704916) that is injected directly into tumors to kill cancer cells. It is being tested alone and with another drug (cetrelimab) in people with advanced solid tumors who have run out of standard treatments. The main goals are to check sa…

This study is testing an experimental chemotherapy drug, JNJ-1761981 ER, that is injected directly into tumors. The goal is to find a safe and effective dose for people with advanced solid tumors who have not responded to other treatments. About 66 participants will take part in …

This study tests a new drug, NBTXR3, that is injected directly into tumors and activated by radiation. It is for patients aged 60 and older with advanced head and neck cancer who cannot receive standard chemotherapy. The goal is to see if adding NBTXR3 to radiation therapy helps …